Article Text

Download PDFPDF

Response to: ‘Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations’ by Orsolini et al
  1. Antonis Fanouriakis1,
  2. George Bertsias2,3,
  3. Dimitrios T Boumpas1,4
  1. 1Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece
  2. 2Department of Rheumatology, University Hospital of Heraklion, Heraklion, Greece
  3. 3Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Crete, Greece
  4. 4Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
  1. Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology, 4th Department of Medicine, "Attikon" University Hospital, Athens, Greece; afanour{at}med.uoa.gr

Statistics from Altmetric.com

We thank Drs Orsolini et al for their interest in the updated European League against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus (SLE),1 and we are grateful for bringing up a crucial aspect of the disease, namely osteoporosis and bone health in patients with this disease. Undoubtedly, prevention and treatment of osteoporosis represent a major challenge and a current unmet need in the holistic management of patients with lupus. The choice …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles